SARS-CoV-2 live virus neutralization after four COVID-19 vaccine doses in people with HIV receiving suppressive antiretroviral therapy.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 04 2023
01 04 2023
Historique:
pubmed:
16
2
2023
medline:
17
3
2023
entrez:
15
2
2023
Statut:
ppublish
Résumé
Limited data exist regarding the immune benefits of fourth COVID-19 vaccine doses in people with HIV (PWH) receiving antiretroviral therapy (ART), particularly now that most have experienced a SARS-CoV-2 infection. We quantified wild-type, Omicron-BA.5 and Omicron-BQ.1-specific neutralization up to 1 month post-fourth COVID-19 vaccine dose in 63 (19 SARS-CoV-2-naive and 44 SARS-CoV-2-experienced) PWH. A longitudinal observational cohort. Quantification of wild-type-, Omicron-BA.5, and Omicron-BQ.1-specific neutralization using live virus assays. Participants received monovalent (44%) and bivalent (56%) mRNA fourth doses. In COVID-19-naive PWH, fourth doses enhanced wild-type and Omicron-BA.5-specific neutralization modestly above three-dose levels ( P = 0.1). In COVID-19-experienced PWH, fourth doses enhanced wild-type specific neutralization modestly ( P = 0.1) and BA.5-specific neutralization substantially ( P = 0.002). Consistent with humoral benefits of 'hybrid' immunity, COVID-19-experienced PWH exhibited the highest neutralization post-fourth dose, wherein those with Omicron-era infections displayed higher wild-type specific ( P = 0.04) but similar BA.5 and BQ.1-specific neutralization than those with pre-Omicron-era infections. Nevertheless, BA.5-specific neutralization was significantly below wild-type in everyone regardless of COVID-19 experience, with BQ.1-specific neutralization lower still (both P < 0.0001). In multivariable analyses, fourth dose valency did not affect neutralization magnitude. Rather, an mRNA-1273 fourth dose (versus a BNT162b2 one) was the strongest correlate of wild-type specific neutralization, while prior COVID-19, regardless of pandemic era, was the strongest correlate of BA.5 and BQ.1-specific neutralization post-fourth dose. Fourth COVID-19 vaccine doses, irrespective of valency, benefit PWH regardless of prior SARS-CoV-2 infection. Results support recommendations that all adults receive a fourth COVID-19 vaccine dose within 6 months of their third dose (or their most recent SARS-CoV-2 infection).
Identifiants
pubmed: 36789806
doi: 10.1097/QAD.0000000000003519
pii: 00002030-202304010-00001
pmc: PMC9994812
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
BNT162 Vaccine
0
COVID-19 Vaccines
0
Types de publication
Journal Article
Observational Study
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
F11-F18Subventions
Organisme : CIHR
ID : GA2–177713
Pays : Canada
Informations de copyright
Copyright © 2023 The Author(s). Published by Wolters Kluwer Health, Inc.
Références
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, et al. People with HIV receiving suppressive antiretroviral therapy show typical antibody durability after dual COVID-19 vaccination, and strong third dose responses . J Infect Dis 2022; jiac229doi:10.1093/infdis/jiac229. [Online ahead of print].
doi: 10.1093/infdis/jiac229.
Vergori A, Cozzi Lepri A, Cicalini S, Matusali G, Bordoni V, Lanini S, et al. Immunogenicity to COVID-19 mRNA vaccine third dose in people living with HIV . Nat Commun 2022; 13:4922.
Fidler S, Fox J, Tipoe T, Longet S, Tipton T, Abeywickrema M, et al. Booster vaccination against SARS-CoV-2 induces potent immune responses in people with HIV . Clin Infect Dis 2023; 76:201–209.
Lapointe HR, Mwimanzi F, Cheung PK, Sang Y, Yaseen F, Speckmaier S, et al. Antibody response durability following three-dose COVID-19 vaccination in people with HIV receiving suppressive ART . AIDS 2023; 37:709–721.
Graham C, Lechmere T, Rehman A, Seow J, Kurshan A, Huettner I, et al. The effect of Omicron breakthrough infection and extended BNT162b2 booster dosing on neutralization breadth against SARS-CoV-2 variants of concern . PLoS Pathog 2022; 18:e1010882.
Kliker L, Zuckerman N, Atari N, Barda N, Gilboa M, Nemet I, et al. COVID-19 vaccination and BA.1 breakthrough infection induce neutralising antibodies which are less efficient against BA.4 and BA.5 Omicron variants, Israel, March to June 2022 . Euro Surveill 2022; 27:2200785.
Hoffmann M, Behrens GMN, Arora P, Kempf A, Nehlmeier I, Cossmann A, et al. Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation . Lancet Infect Dis 2023; 23:25–28.
Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, et al. A bivalent Omicron-containing booster vaccine against Covid-19 . N Engl J Med 2022; 387:1279–1291.
COVID-19 update: bivalent Pfizer and Moderna COVID-19 vaccines for booster immunization . Med Lett Drugs Ther 2022; 64:159–160.
Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Yaseen F, Umviligihozo G, et al. Older adults mount less durable humoral responses to two doses of COVID-19 mRNA vaccine, but strong initial responses to a third dose . J Infect Dis 2022; 226:983–994.
Brumme ZL, Mwimanzi F, Lapointe HR, Cheung PK, Sang Y, Duncan MC, et al. Humoral immune responses to COVID-19 vaccination in people living with HIV receiving suppressive antiretroviral therapy . NPJ Vaccines 2022; 7:28.
National Advisory Committee on Immunization. NACI rapid response: extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada. National Advisory Committee on Immunization (NACI). 2021.
National Advisory Committee on Immunization. Extended dose intervals for COVID-19 vaccines to optimize early vaccine rollout and population protection in Canada in the context of limited vaccine supply. National Advisory Committee on Immunization (NACI). 2021.
BC Ministry of Health. COVID-19 vaccines. Immunize BC. https://immunizebc.ca/covid-19 . [Accessed 3 January 2023]
BC Centre for Disease Control. Weekly update on variants of concern. http://www.bccdc.ca/health-info/diseases-conditions/covid-19/data . [Accessed 3 January 2023]
Gilbert PB, Montefiori DC, McDermott AB, Fong Y, Benkeser D, Deng W, et al. Immune correlates analysis of the mRNA-1273 COVID-19 vaccine efficacy clinical trial . Science 2022; 375:43–50.
Khoury DS, Cromer D, Reynaldi A, Schlub TE, Wheatley AK, Juno JA, et al. Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection . Nat Med 2021; 27:1205–1211.
Lamacchia G, Salvati L, Kiros ST, Mazzoni A, Vanni A, Capone M, et al. Fourth dose of mRNA COVID-19 vaccine transiently reactivates spike-specific immunological memory in people living with HIV (PLWH) . Biomedicines 2022; 10:3261.
Regev-Yochay G, Gonen T, Gilboa M, Mandelboim M, Indenbaum V, Amit S, et al. Efficacy of a fourth dose of Covid-19 mRNA vaccine against Omicron . N Engl J Med 2022; 386:1377–1380.
Wang Z, Muecksch F, Schaefer-Babajew D, Finkin S, Viant C, Gaebler C, et al. Naturally enhanced neutralizing breadth against SARS-CoV-2 one year after infection . Nature 2021; 595:426–431.
Zaballa ME, Perez-Saez J, de Mestral C, Pullen N, Lamour J, Turelli P, et al. Seroprevalence of anti-SARS-CoV-2 antibodies and cross-variant neutralization capacity after the Omicron BA.2 wave in Geneva, Switzerland: a population-based study . Lancet Reg Health Eur 2022; 24:100547.
Khan K, Karim F, Ganga Y, Bernstein M, Jule Z, Reedoy K, et al. Omicron BA.4/BA . 5 escape neutralizing immunity elicited by BA 1 infection Nat Commun 2022; 13:4686.
Aggarwal A, Akerman A, Milogiannakis V, Silva MR, Walker G, Stella AO, et al. SARS-CoV-2 Omicron BA.5: evolving tropism and evasion of potent humoral responses and resistance to clinical immunotherapeutics relative to viral variants of concern . EBioMedicine 2022; 84:104270.
Cao Y, Yisimayi A, Jian F, Song W, Xiao T, Wang L, et al. BA.2.12.1, BA.4 and BA.5 escape antibodies elicited by Omicron infection . Nature 2022; 608:593–602.
Qu P, Evans JP, Faraone JN, Zheng YM, Carlin C, Anghelina M, et al. Enhanced neutralization resistance of SARS-CoV-2 Omicron subvariants BQ.1, BQ.1.1, BA.4.6, BF.7, and BA.2.75.2 . Cell Host Microbe 2023; 31:9–17.e3.
Jiang XL, Zhu KL, Wang XJ, Wang GL, Li YK, He XJ, et al. Omicron BQ.1 and BQ.1.1 escape neutralisation by omicron subvariant breakthrough infection . Lancet Infect Dis 2023; 23:28–30.
Link-Gelles R, Ciesla AA, Roper LE, Scobie HM, Ali AR, Miller JD, et al. Early estimates of bivalent mRNA booster dose vaccine effectiveness in preventing symptomatic SARS-CoV-2 infection attributable to Omicron BA.5- and XBB/XBB.1.5-related sublineages among immunocompetent adults: increasing community access to Testing Program, United States, December 2022-January . MMWR Morb Mortal Wkly Rep 2023; 72:119–124.
Lin DY, Xu Y, Gu Y, Zeng D, Wheeler B, Young H, et al. Effectiveness of bivalent boosters against severe Omicron infection . N Engl J Med 2023; doi: 10.1056/NEJMc2215471. [Online ahead of print].
doi: 10.1056/NEJMc2215471.
Frater J, Ewer KJ, Ogbe A, Pace M, Adele S, Adland E, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in HIV infection: a single-arm substudy of a phase 2/3 clinical trial . Lancet HIV 2021; 8:e474–e485.
Woldemeskel BA, Karaba AH, Garliss CC, Beck EJ, Wang KH, Laeyendecker O, et al. The BNT162b2 mRNA vaccine elicits robust humoral and cellular immune responses in people living with human immunodeficiency virus (HIV) . Clin Infect Dis 2022; 74:1268–1270.
Madhi SA, Koen AL, Izu A, Fairlie L, Cutland CL, Baillie V, et al. Safety and immunogenicity of the ChAdOx1 nCoV-19 (AZD1222) vaccine against SARS-CoV-2 in people living with and without HIV in South Africa: an interim analysis of a randomised, double-blind, placebo-controlled, phase 1B/2A trial . Lancet HIV 2021; 8:e568–e580.
Hassold N, Brichler S, Ouedraogo E, Leclerc D, Carroue S, Gater Y, et al. Impaired antibody response to COVID-19 vaccination in advanced HIV infection . AIDS 2022; 36:F1–F5.
Spinelli MA, Peluso MJ, Lynch KL, Yun C, Glidden DV, Henrich TJ, et al. Differences in Post-mRNA vaccination severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) immunoglobulin G (IgG) concentrations and surrogate virus neutralization test response by human immunodeficiency virus (HIV) status and type of vaccine: a matched case-control observational study . Clin Infect Dis 2022; 75:e916–e919.
Tuan JJ, Zapata H, Critch-Gilfillan T, Ryall L, Turcotte B, Mutic S, et al. Qualitative assessment of anti-SARS-CoV-2 spike protein immunogenicity (QUASI) after COVID-19 vaccination in older people living with HIV . HIV Med 2022; 23:178–185.
Antinori A, Cicalini S, Meschi S, Bordoni V, Lorenzini P, Vergori A, et al. Humoral and cellular immune response elicited by mRNA vaccination against severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) in people living with human immunodeficiency virus receiving antiretroviral therapy based on current CD4 T-lymphocyte count . Clin Infect Dis 2022; 75:e552–e563.
Jedicke N, Stankov MV, Cossmann A, Dopfer-Jablonka A, Knuth C, Ahrenstorf G, et al. Humoral immune response following prime and boost BNT162b2 vaccination in people living with HIV on antiretroviral therapy . HIV Med 2022; 23:558–563.
Ismail SJ, Young K, Tunis MC, Killikelly A, Stirling R, Baclic O , et al. COVID-19 vaccine: Canadian Immunization Guide. Health Canada; 2022.
Canetti M, Barda N, Gilboa M, Indenbaum V, Mandelboim M, Gonen T, et al. Immunogenicity and efficacy of fourth BNT162b2 and mRNA1273 COVID-19 vaccine doses; three months follow-up . Nat Commun 2022; 13:7711.